Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $14.29 per share which beat the analyst consensus estimate of $10.26 by 39.28 percent. This is a 10.86 percent increase over earnings of $12.89 per share from the same period last year. The company reported quarterly sales of $4.291 billion which beat the analyst consensus estimate of $3.816 billion by 12.44 percent. This is a 16.60 percent increase over sales of $3.680 billion the same period last year.